NSD2 and plasma cell myeloma: Additionally, NSD2 has been demonstrated to support the proliferation and/or survival of several cancer cell lines including myeloma cell lines with t(4;14) translocations15, 16, 17, 18, leukemia cell lines carrying the E1099K mutation4, prostate cancer14, 19, 20 and osteo and fibrosarcoma cell lines15.